Who are DiaMedica Therapeutics's investors?

DiaMedica Therapeutics's investors include CentreStone Ventures, Shepherd Ventures.

How much funding has DiaMedica Therapeutics raised?

DiaMedica Therapeutics has disclosed $110.4M raised across 6 rounds.

Where is DiaMedica Therapeutics headquartered?

DiaMedica Therapeutics is headquartered in Minneapolis, US.

DiaMedica Therapeutics

NASDAQ: DMAC

Minneapolis, US · Canada (Federal Level) corporation · 2 known investors

Find your way into DiaMedica Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the DiaMedica Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

DiaMedica Therapeutics develops therapies aimed at reducing ischemia in patients with serious vascular diseases, with an initial focus on preeclampsia, fetal growth restriction, and acute ischemic stroke. It is a clinical-stage biopharmaceutical company working on treatments for ischemic disorders.

Biotech Digital Health

Founders & leadership

David J. Wambeke Chief Business Officer2023–2025David J. Wambeke is an Executive Officer at DiaMedica Therapeutics, a clinical-stage biopharmaceutical company developing therapies for ischemic disorders. He is a former healthcare investment banker and U.S. Army combat veteran.

Lorianne Masuoka Chief Medical Officer2024–2025Lorianne Masuoka is an executive officer at DiaMedica Therapeutics, a clinical-stage biopharmaceutical company developing therapies to reduce ischemia in patients with serious vascular diseases, including preeclampsia, fetal growth restriction, and acute ischemic stroke. She has expertise in neurology and related therapeutic areas.

Rick Pauls President & CEORick Pauls is an Executive Officer and Director at DiaMedica Therapeutics, a clinical-stage biopharmaceutical company developing therapies for ischemic diseases including acute ischemic stroke and preeclampsia.

Scott Kellen Chief Financial OfficerScott Kellen is an executive officer at DiaMedica Therapeutics, a clinical-stage biopharmaceutical company developing therapies for ischemic disorders including preeclampsia and acute ischemic stroke. He brings financial and operational management experience, with expertise in capital formation, SEC compliance, financial planning, and corporate governance.

Todd Verdoorn Chief Scientific Officer2016–2019Todd Verdoorn is an executive officer at DiaMedica Therapeutics, a clinical-stage biopharmaceutical company developing therapies for ischemic disorders. He has led drug and device development programs from preclinical through clinical stages across multiple companies and disease areas, with experience in manufacturing, toxicology, biomarkers, and translational medicine.

Julie Krop Chief Medical OfficerJulie Krop is Chief Medical Officer of DiaMedica Therapeutics, a clinical-stage biopharmaceutical company developing therapies for ischemic vascular disorders. She has held senior clinical development and regulatory affairs roles at large pharmaceutical and biotech companies, with experience spanning early-stage through post-approval drug development and FDA interactions.

Paul PapiNamed on SEC filing

Zhenyu (Jerry) XiaoNamed on SEC filing

David GurveyNamed on SEC filing

Board

Charles P. SembaBoard director

Richard KuntzBoard directorManaging Director at Shepherd Ventures

R. Michael GiuffreBoard director

Investors · 2

CentreStone VenturesreportedWinnipeg · $182.5K – $1.8M

How we know: the S-1 prospectus · funding news · Not right? Tell us

Shepherd VenturesinferredSan Diego · $750K – $3Mvia Richard P. Kuntz · board

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$110.4M disclosed across 6 rounds · 2018–2025

▶$30.1MraisedJul 2025 · 14 investors · Biotechnology

Rule 506(b)